PLAT

PLAT Full Name

plasminogen activator, tissue

PLAT Introduction

PLAT, which encodes tissue-type plasminogen activator (tPA), is best known for its central role in the fibrinolytic system, where it catalyzes the conversion of plasminogen into plasmin and enables the breakdown of fibrin clots. For researchers and clinicians working in thrombosis, stroke, or vascular biology, PLAT represents a critical control point linking coagulation, vascular permeability, and tissue remodeling. Beyond its classical vascular function, PLAT is expressed in multiple tissues, including the brain and epithelial surfaces, making it highly relevant for studies that aim to understand why dysregulated proteolysis and extracellular matrix turnover often complicate disease progression and limit therapeutic outcomes.

Recent evidence has expanded the functional landscape of PLAT, particularly in neurobiology and inflammation. A 2024 study using PC-12 neuron-like cells demonstrated that PLAT overexpression leads to significant transcriptomic changes, suggesting that PLAT may influence neuronal metabolism or intracellular signaling rather than acting solely as an extracellular protease. This finding is especially meaningful for ischemic brain injury and neurodegenerative disease research, where tPA has been implicated in synaptic plasticity, blood–brain barrier integrity, and post-ischemic remodeling. In parallel, respiratory inflammation studies have shown that reduced PLAT expression in chronic rhinosinusitis with nasal polyps is associated with excessive fibrin deposition and tissue edema, highlighting how impaired local fibrinolysis can directly worsen chronic inflammatory pathology and treatment resistance.

PLAT is also gaining attention in oncology as a context-dependent regulator of tumor behavior and a potential biomarker. Bioinformatics analyses of pancreatic cancer cohorts have identified PLAT as a key insulin-driven gene whose elevated expression correlates with patient prognosis, pointing to its value in risk stratification and outcome prediction. In non-small cell lung cancer, PLAT has been linked to drug resistance mechanisms; modulation of the PLAT/FAK/AKT axis was shown to reduce migration and invasion in gefitinib-resistant cells, suggesting a role in extracellular matrix degradation and tumor microenvironment remodeling. Together, these findings position PLAT as more than a fibrinolytic enzyme—it is an emerging cross-disease target connecting vascular biology, inflammation, neural regulation, and cancer progression, with clear implications for biomarker discovery and mechanism-driven therapeutic research.

Alternate Names for PLAT

PLAT; plasminogen activator, tissue; tPA; AU020998; AW212668; D8Ertd2e; tissue-type plasminogen activator; t-plasminogen activator;

• 1. Mao Y, et al.; RNA sequencing reveals transcriptomic changes in PC-12 cells following plasminogen activator, tissue type overexpression. Transl Cancer Res. 2024, 13(9):4866-4877.